■非侵入性,简单,和评估表皮生长因子受体(EGFR)突变的简便方法对于肺腺癌的初始治疗决策很重要。
■我们回顾性分析了297例未治疗的原发性肺腺癌患者的确切EGFR状态。根据他们的EGFR状态,患者分为突变型组(138例)和野生型组(159例).还评估了患者的一般特征和反映EGFR状态的可能因素。
■在2013年1月至2017年12月期间接受正电子发射断层扫描(PET)/计算机断层扫描(CT)的297例肺腺癌患者中,有138例(46.5%)检测到EGFR基因突变。EGFR突变更频繁地与女性相关,从不吸烟者,和低18F-氟-2-脱氧-葡萄糖(18F-FDG)PET/CT原发性肿瘤的最大标准摄取值(pSUVmax)。多因素分析显示女性[比值比(OR)=2.853;95%置信区间(CI):1.451-5.611;P=0.002],从不吸烟者(OR=2.414;95%CI:1.217-4.789;P=0.012),肿瘤大小<3.5cm(或,2.170;95%CI:1.205-3.908;P=0.010),pSUVmax<8.2(OR=1.904;95%CI:1.098-3.302;P=0.022)是EGFR突变的有效预测因子。此外,pSUVmax和肿瘤大小的曲线下面积(AUC)分别为0.623和0.600。结合临床特点,包括性别和吸烟状况,4个预测因子的AUC为0.770.
■这些指标可能有助于提高肺腺癌患者EGFR突变的预测准确性,尤其是那些无法进行EGFR检测的患者.
UNASSIGNED: A non-invasive, simple, and convenient method to evaluate the presence of epidermal growth factor receptor (EGFR) mutations is important for initial treatment decisions in lung adenocarcinoma.
UNASSIGNED: We retrospectively reviewed 297 untreated primary lung adenocarcinoma patients with exact EGFR status. Based on their EGFR status, the patients were divided into a mutant-type group (138 patients) and wild-type group (159 patients). General patient characteristics and possible factors reflecting the status of EGFR were also evaluated.
UNASSIGNED: Of the 297 lung adenocarcinoma patients analyzed for EGFR status who underwent positron emission tomography (PET)/computed tomography (CT) between January 2013 and December 2017, mutations in the EGFR gene were detected in 138 patients (46.5%). EGFR mutations were more frequently associated with women, never smokers, and low 18F-fluoro-2-deoxy-glucose (18F-FDG) PET/CT maximal standard uptake value of the primary tumor (pSUVmax). Multivariate analysis indicated that women [odds ratio (OR) =2.853; 95% confidence interval (CI): 1.451-5.611; P=0.002], never smokers (OR =2.414; 95% CI: 1.217-4.789; P=0.012), tumor size <3.5 cm (OR, 2.170; 95% CI: 1.205-3.908; P=0.010), and pSUVmax <8.2 (OR =1.904; 95% CI: 1.098-3.302; P=0.022) were effective predictors of EGFR mutation. In addition, the area under the curve (AUC) of pSUVmax and tumor size was 0.623 and 0.600, respectively. Combined with clinical characteristics, including sex and smoking status, the AUC of the 4 predictors was 0.770.
UNASSIGNED: These indicators could be helpful for enhancing predictive accuracy of EGFR mutations in lung adenocarcinoma patients, especially in those for whom EGFR detection is unavailable.